Memantina Mabo (Memantine Hydrochloride)

Memantina Mabo is a NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease and related cognitive disorders.

• Moderate to severe Alzheimer’s disease: improves cognition, daily functioning and global clinical status.
• Mild to moderate Alzheimer’s disease (as adjunct to cholinesterase inhibitors): may provide additional cognitive benefit.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury and supporting neuronal survival in the brain.

Memantina Mabo may be associated with a range of adverse reactions.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: transient cranial discomfort.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness or lack of energy.
• Confusion: temporary disorientation or difficulty concentrating.

Serious or Rare Side Effects

• Seizures: rare occurrence of convulsive episodes.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Hallucinations: visual or auditory disturbances.
• Hyponatremia: low blood sodium levels, potentially causing weakness or confusion.

Before prescribing Memantina Mabo, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function.
• Hepatic disease: use with caution in patients with liver dysfunction.
• History of seizures: evaluate risk as memantine may lower seizure threshold.
• Concomitant use with other NMDA antagonists: avoid additive neuro‑psychiatric effects.
• Pregnancy and lactation: safety not established; weigh potential benefits against risks.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Memantina Mabo can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neuro‑psychiatric adverse effects.
• Ketamine: additive NMDA blockade can exacerbate CNS depression.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors (e.g., donepezil): monitor for enhanced cognitive effects.
• Diuretics (e.g., furosemide): may increase risk of hyponatremia.
• CNS depressants (e.g., benzodiazepines): observe for increased sedation.